Sugi Predict

Sugi Predict / Compounds / SCHEMBL17873805

SCHEMBL17873805

SCHEMBL17873805

O=C1CCC(N2C(=O)c3cccc([N+](=O)[O-])c3C2=O)C(=O)N1Cc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DDB1 Q16531 4/20 0.60
▸ CRBN Q96SW2 4/20 0.60
▸ ACHE P22303 2/20 0.53
▸ MEN1 O00255 2/20 0.50
▸ KMT2A Q03164 2/20 0.50
▸ ATM Q13315 1/20 0.48
▸ CA1 P00915 2/20 0.47
▸ CA2 P00918 2/20 0.47
▸ CA9 Q16790 2/20 0.47
▸ CA12 O43570 1/20 0.47
▸ CA4 P22748 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ TDP1 Q9NUW8 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ POLB P06746 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ APEX1 P27695 1/20 0.39
▸ RECQL P46063 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19359396 0.86 DDB1 (0.60) DDB1CRBNACHEMEN1KMT2A
SCHEMBL19359463 0.84 DDB1 (0.58) DDB1CRBNACHEMEN1KMT2A
SCHEMBL4936560 0.84 DDB1 (0.58) DDB1CRBNACHEMEN1KMT2A
SCHEMBL19359289 0.84 DDB1 (0.58) DDB1CRBNACHEMEN1KMT2A
SCHEMBL17884573 0.84 DDB1 (0.56) DDB1CRBNACHEMEN1KMT2A
SCHEMBL5617530 0.84 DDB1 (0.57) DDB1CRBNACHEMEN1KMT2A
SCHEMBL4120260 0.83 ALDH1A1 (0.50) DDB1CRBNACHEMEN1KMT2A
SCHEMBL29357653 0.83 DDB1 (0.57) DDB1CRBNMEN1KMT2AALDH1A1
SCHEMBL4937839 0.82 DDB1 (0.55) DDB1CRBNACHEMEN1KMT2A
SCHEMBL31488340 0.82 DDB1 (0.47) DDB1CRBNACHECA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12023385-B2 Tunable endogenous protein degradation with heterobifunctional compounds DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-07-02 — — US disclosed
EP-3256470-B1 METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES DANA FARBER CANCER INST INC (US) 2023-07-26 — — EP disclosed
EP-4119552-A1 REGULATING CHIMERIC ANTIGEN RECEPTORS Dana-Farber Cancer Institute, Inc. (US) 2023-01-18 — — EP disclosed
CN-108350062-B Targeted protein degradation to attenuate adverse inflammatory responses associated with adoptive T cell therapy 达纳-法伯癌症研究所股份有限公司 2022-10-14 — — CN disclosed
EP-3331905-B1 TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES DANA FARBER CANCER INST INC (US) 2022-10-05 — — EP disclosed
US-20220135967-A1 TUNABLE ENDOGENOUS PROTEIN DEGRADATION DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-05-05 — — US disclosed
US-11311609-B2 Regulating chimeric antigen receptors DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-04-26 — — US disclosed
US-11293023-B2 Tunable endogenous protein degradation DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-04-05 — — US disclosed
US-20210301286-A1 TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-09-30 — — US disclosed
US-11059801-B2 Methods to induce targeted protein degradation through bifunctional molecules DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-07-13 — — US disclosed
US-10125114-B2 Methods to induce targeted protein degradation through bifunctional molecules DANA-FARBER CANCER INSTITUTE, INC. (US) 2018-11-13 — — US disclosed
WO-2018148443-A1 TUNABLE ENDOGENOUS PROTEIN DEGRADATION WITH HETEROBIFUNCTIONAL COMPOUNDS DANA-FARBER CANCER INSTITUTE, INC. (US) 2018-08-16 — — WO disclosed
US-20180179522-A1 TUNABLE ENDOGENOUS PROTEIN DEGRADATION DANA-FARBER CANCER INSTITUTE, INC. (US) 2018-06-28 — — US disclosed
US-20180169109-A1 TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES DANA-FARBER CANCER INSTITUTE, INC. (US) 2018-06-21 — — US disclosed
EP-3331905-A1 TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES Dana-Farber Cancer Institute, Inc. (US) 2018-06-13 — — EP disclosed
US-20180134684-A1 METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES DANA-FARBER CANCER INSTITUTE, INC. (US) 2018-05-17 — — US disclosed
US-20180009779-A1 METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES DANA-FARBER CANCER INSTITUTE, INC. (US) 2018-01-11 — — US disclosed
EP-3256470-A1 METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES Dana Farber Cancer Institute, Inc. (US) 2017-12-20 — — EP disclosed
WO-2017024318-A1 TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-02-09 — — WO disclosed
WO-2016105518-A1 METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-06-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210301286-A1 TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES NFATC1, GZMB, ICOS DDB1 940/4885CRBN 97/4885ACHE 4519/4885
US-20180009779-A1 METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES CRBN, MDM2, MYCBP DDB1 113/4885CRBN 1/4885ACHE 4112/4885
US-20180169109-A1 TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES NFATC1, GZMB, ICOS DDB1 940/4885CRBN 97/4885ACHE 4519/4885
US-20180179522-A1 TUNABLE ENDOGENOUS PROTEIN DEGRADATION PSMG3, MYCBP, DBN1 DDB1 26/4885CRBN 138/4885ACHE 4626/4885
US-11059801-B2 Methods to induce targeted protein degradation through bifunctional molecules CRBN, XIAP, MDM2 DDB1 110/4885CRBN 1/4885ACHE 3882/4885
US-12023385-B2 Tunable endogenous protein degradation with heterobifunctional compounds DBN1, MYCBP, PSMG3 DDB1 10/4885CRBN 158/4885ACHE 4540/4885
US-10125114-B2 Methods to induce targeted protein degradation through bifunctional molecules CRBN, MDM2, MYCBP DDB1 113/4885CRBN 1/4885ACHE 4112/4885
US-11293023-B2 Tunable endogenous protein degradation PSMG3, MYCBP, DBN1 DDB1 26/4885CRBN 138/4885ACHE 4626/4885
US-11311609-B2 Regulating chimeric antigen receptors NFATC1, TNFRSF9, IL2RA DDB1 979/4885CRBN 154/4885ACHE 4423/4885
US-20180134684-A1 METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES CRBN, MDM2, MYCBP DDB1 113/4885CRBN 1/4885ACHE 4112/4885
US-20220135967-A1 TUNABLE ENDOGENOUS PROTEIN DEGRADATION PSMG3, MYCBP, DBN1 DDB1 26/4885CRBN 138/4885ACHE 4626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.